LONDON - GSK plc has made a strategic move to enhance its respiratory disease treatment portfolio by acquiring biotechnology firm Aiolos Bio, Inc. The deal, valued at $1 billion with an additional $400 million contingent on reaching regulatory milestones, positions GSK to potentially transform asthma care.
Aiolos Bio has been developing AIO-001, an innovative long-acting anti-TSLP monoclonal antibody. This treatment stands out for its biannual dosing schedule, which could significantly improve patient convenience and adherence. Moreover, AIO-001 is not just limited to asthma; it also has potential applications in treating chronic rhinosinusitis with nasal polyps.
The acquisition comes as AIO-001 is advancing into phase II clinical trials, indicating its promise in a global market with over 315 million individuals living with asthma. The completion of GSK's acquisition is pending approval under the Hart-Scott-Rodino Act, which ensures that the deal complies with antitrust laws and maintains market competition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.